Millipore Sigma Vibrant Logo

ALP10-KC Apolipoprotein A-I, human (1mg) KC

View Products on Sigmaaldrich.com
ALP10-KC
Bulk packaging. Please inquire.  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information
      Description
      Catalogue NumberALP10-KC
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionApolipoprotein A-I, human (1mg) KC
      OverviewThis product is intended for use by IVD manufacturers.
      Contact customer service for assistance: oem.reagents@emdmillipore.com
      Alternate Names
      • ApoAI
      References
      Product Information
      PresentationLiquid in 10 mM NH4HCO3, pH 7.4. Non-sterile, no preservatives.
      Quality LevelMQ300
      Applications
      Key Applications
      • Positive Control
      Biological Information
      Concentration1.35 mg/mL
      Purity> 98%.

      High Density Lipoprotein (HDL) isolated by ultracentrifugation are delipidated. Apo A-I is purified by column chromatography in 6M urea (Schonfeld et al. 1977). Purity is determined by quantitative densitometric of SDS polyacrylamide gels (Laemlli 1970). Protein is determined by the Pierce BCA method (which was found to be comparable to the Lowry method) with BSA as the standard.

      MOLECULAR WEIGHT:
      28,000
      SourceNormal human plasma, fresh, non-frozen. Tested negative for HIV-1, HIV-2, HCV and HBc antibodies and HBsAg.
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.
      Gene Symbol
      • APOA1
      • ApoA-I
      • MGC117399
      • preproapolipoprotein
      • amyloidosis
      • Apo-AI
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P02647 # Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT).
      SIZE: 267 amino acids; 30778 Da
      SUBUNIT: Interacts with APOA1BP.
      SUBCELLULAR LOCATION: Secreted.
      TISSUE SPECIFICITY: Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
      PTM: Palmitoylated.
      DISEASE: SwissProt: P02647 # Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant. & Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I. & Defects in APOA1 are a cause of systemic non-neuropathic amyloidosis [MIM:105200]; also known as amyloidosis VIII or Ostertag-type amyloidosis. It is an autosomal dominant disorder characterized by generalized amyloid deposition.
      SIMILARITY: SwissProt: P02647 ## Belongs to the apolipoprotein A1/A4/E family.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain lyophilized material at < -20°C for up to six months. Maintain reconstituted Apo A-I at +4°C up to 4 weeks. Freezing solutions of apolipoproteins in the absence of denaturants may favor increased self-association or aggregation.
      Packaging Information
      Material SizeBulk packaging. Please inquire.
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      ALP10-KC 04053252482571

      Documentation

      Produits & Applications associés

      Alternative Packsize

      Référence Description  
      ALP10 Apolipoprotein A-I, human Prix & Disponibilité

      Produits associés classés par : Brand Facete

      Calbiochem®
      Upstate®

      Catégories

      IVD/OEM Materials & Reagents > Bulk & Custom Antibodies > Primary Bulk Antibodies by Target > Lipoproteins
      Life Science Research > Proteins and Enzymes > Other Proteins